University of Sussex
MERGED Revised CEA BJC MAY unmarked 2017 i.pdf (873.45 kB)

The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

Download (873.45 kB)
journal contribution
posted on 2023-06-09, 06:36 authored by Usha Menion, Alistair McGuire, Maria Raikou, Andy Ryan, Susan Davies, Matthew Burnell, Aleksandra Gentry-Maharaj, Jatinderpal Kalsi, Naveena Singh, Nazar Amso, Derek Cruickshank, Stephen Dobbs, Keith Godfrey, Jonathan Herod, Simon Leeson, Tim Mould, John Murdoch, David Oram, Ian Scott, Mourad Seif, Karin Williamson, Robert Woolas, Lesley FallowfieldLesley Fallowfield, Stuart Campbell, Steven Skates, Mahesh Parmar, Ian Jacobs
Background: To assess the within trial cost-effectiveness of an NHS ovarian cancer screening (OCS) programme using data from UKCTOCS and extrapolate results based on average life expectancy. Methods: Within trial economic evaluation of no screening (C) versus either (1) an annual OCS programme using transvaginal ultrasound (USS) or (2) an annual ovarian cancer multimodal screening programme with serum CA125 interpreted using a risk algorithm (ROCA) and transvaginal ultrasound as a second line test (MMS), plus comparison of lifetime extrapolation of the no screening arm and the MMS programme using both a predictive and a Markov model. Results: Using a CA125-ROCA cost of £20, the within trial results show USS to be strictly dominated by MMS, with the MMS versus C comparison returning an Incremental Cost-Effectiveness ratio (ICER) of £91,452 per life year gained (LYG). If the CA125-ROCA unit cost is reduced to £15 the ICER becomes £77,818 per LYG. Predictive extrapolation over the expected lifetime of the UKCTOCS women returns an ICER of £30,033 per LYG, while Markov modelling produces an ICER of £46,922 per QALY. Conclusions: Analysis suggests that, after accounting for the lead-time required to establish full mortality benefits, a national OCS programme based on the MMS strategy quickly approaches the current NICE thresholds for cost-effectiveness when extrapolated out to lifetime as compared to the within trial ICER estimates. Whether MMS could be recommended on economic grounds would depend on the confirmation and size of the mortality benefit at the end of an ongoing follow-up of the UKCTOCS cohort.


UKCTOCS; Medical Research Council


Publication status

  • Published

File Version

  • Accepted version


British Journal of Cancer




Nature Publishing Group



Page range


Department affiliated with

  • Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date


First Open Access (FOA) Date


First Compliant Deposit (FCD) Date


Usage metrics

    University of Sussex (Publications)


    No categories selected